Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women
Journal
Journal of the Formosan Medical Association
Journal Volume
114
Journal Issue
8
Pages
710-716
Date Issued
2015
Author(s)
Tu S.-T.
Wu J.-S.
Chang C.-I.
Peng H.-Y.
Wang S.-Y.
Wu C.-H.
Hsu S.-C.
Liu C.-W.
Abstract
Background/Purpose: Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion: The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors. ? 2013.
SDGs
Other Subjects
alanine aminotransferase; antigen; aspartate aminotransferase; blood clotting factor 7; D dimer; isoflavone; placebo; plasminogen activator inhibitor 1; triacylglycerol; von Willebrand factor; biological marker; blood clotting factor; isoflavone derivative; phytoestrogen; adult; aged; alanine aminotransferase blood level; Article; blood biochemistry; blood clotting; blood clotting test; blood pressure; body weight; cholesterol blood level; controlled study; drug effect; drug megadose; endothelial microparticle; female; fibrinolysis; hematological parameters; human; liver function test; membrane microparticle; monocyte; outcome assessment; postmenopause; randomized controlled trial; thrombocyte; blood; blood clotting; clinical trial; double blind procedure; drug effects; membrane microparticle; metabolism; middle aged; multicenter study; normal human; prospective study; Taiwan; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Cell-Derived Microparticles; Double-Blind Method; Female; Healthy Volunteers; Humans; Isoflavones; Middle Aged; Phytoestrogens; Postmenopause; Prospective Studies; Taiwan
Publisher
Elsevier B.V.
Type
journal article